Sartorius Valuation
Is SRT3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SRT3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SRT3 (€209.8) is trading below our estimate of fair value (€290.87)
Significantly Below Fair Value: SRT3 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SRT3?
Key metric: As SRT3 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is SRT3's PS Ratio? | |
|---|---|
| PS Ratio | 4.4x |
| Sales | €3.32b |
| Market Cap | €13.43b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.6x |
| Enterprise Value/EBITDA | 24.1x |
| PEG Ratio | 5.1x |
Price to Sales Ratio vs Peers
How does SRT3's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2x | ||
1SXP SCHOTT Pharma KGaA | 4.1x | 10.7% | €3.9b |
GXI Gerresheimer | 1.2x | 10.2% | €2.5b |
EVT Evotec | 2.4x | 12.1% | €1.9b |
BAYN Bayer | 0.4x | 1.1% | €19.9b |
SRT3 Sartorius | 4.4x | 9.3% | €13.1b |
Price-To-Sales vs Peers: SRT3 is expensive based on its Price-To-Sales Ratio (4.4x) compared to the peer average (2x).
Price to Sales Ratio vs Industry
How does SRT3's PS Ratio compare vs other companies in the European Life Sciences Industry?
| 5 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: SRT3 is expensive based on its Price-To-Sales Ratio (4.4x) compared to the European Life Sciences industry average (4.3x).
Price to Sales Ratio vs Fair Ratio
What is SRT3's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 4.4x |
| Fair PS Ratio | 4.2x |
Price-To-Sales vs Fair Ratio: SRT3 is expensive based on its Price-To-Sales Ratio (4.4x) compared to the estimated Fair Price-To-Sales Ratio (4.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €209.80 | €265.89 +26.7% | 13.1% | €320.00 | €173.00 | n/a | 19 |
| Nov ’25 | €243.50 | €265.94 +9.2% | 13.5% | €320.00 | €173.00 | n/a | 18 |
| Oct ’25 | €246.90 | €263.28 +6.6% | 14.9% | €320.00 | €173.00 | n/a | 18 |
| Sep ’25 | €249.40 | €265.88 +6.6% | 15.9% | €335.00 | €173.00 | n/a | 17 |
| Aug ’25 | €261.70 | €271.53 +3.8% | 17.8% | €375.00 | €173.00 | n/a | 17 |
| Jul ’25 | €211.70 | €314.88 +48.7% | 13.9% | €380.00 | €210.00 | n/a | 16 |
| Jun ’25 | €241.50 | €318.63 +31.9% | 13.1% | €380.00 | €210.00 | n/a | 16 |
| May ’25 | €282.30 | €330.50 +17.1% | 11.7% | €400.00 | €240.00 | n/a | 16 |
| Apr ’25 | €368.60 | €349.75 -5.1% | 11.9% | €415.00 | €240.00 | n/a | 16 |
| Mar ’25 | €351.70 | €334.94 -4.8% | 12.8% | €390.00 | €240.00 | n/a | 16 |
| Feb ’25 | €338.80 | €319.81 -5.6% | 13.6% | €390.00 | €235.00 | n/a | 16 |
| Jan ’25 | €333.20 | €287.64 -13.7% | 9.3% | €340.00 | €235.00 | n/a | 14 |
| Dec ’24 | €288.10 | €281.57 -2.3% | 9.6% | €340.00 | €240.00 | n/a | 14 |
| Nov ’24 | €242.20 | €303.80 +25.4% | 19.0% | €470.00 | €240.00 | €243.50 | 15 |
| Oct ’24 | €321.80 | €368.07 +14.4% | 14.0% | €470.00 | €250.00 | €246.90 | 14 |
| Sep ’24 | €370.90 | €369.29 -0.4% | 13.8% | €470.00 | €250.00 | €249.40 | 14 |
| Aug ’24 | €365.50 | €365.36 -0.04% | 14.3% | €470.00 | €250.00 | €261.70 | 14 |
| Jul ’24 | €317.10 | €373.83 +17.9% | 22.0% | €603.60 | €250.00 | €211.70 | 14 |
| Jun ’24 | €321.00 | €427.51 +33.2% | 16.9% | €603.60 | €320.00 | €241.50 | 13 |
| May ’24 | €351.60 | €441.74 +25.6% | 17.3% | €603.60 | €320.00 | €282.30 | 13 |
| Apr ’24 | €387.00 | €460.82 +19.1% | 16.9% | €603.60 | €320.00 | €368.60 | 13 |
| Mar ’24 | €399.40 | €455.43 +14.0% | 18.2% | €603.60 | €320.00 | €351.70 | 13 |
| Feb ’24 | €417.50 | €449.05 +7.6% | 18.9% | €603.60 | €295.00 | €338.80 | 13 |
| Jan ’24 | €369.40 | €451.43 +22.2% | 21.9% | €603.60 | €267.00 | €333.20 | 12 |
| Dec ’23 | €371.10 | €455.16 +22.7% | 21.1% | €603.60 | €267.00 | €288.10 | 13 |
| Nov ’23 | €344.00 | €436.11 +26.8% | 23.3% | €570.00 | €260.01 | €242.20 | 14 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Aspen Pharmacare Holdings
R76.0b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R8.90
7D
-4.3%
1Y
4.7%
Fortrea Holdings
US$1.7b
A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.
K67
US$18.70
7D
-14.2%
1Y
-35.1%
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.44
7D
-3.9%
1Y
-4.0%